MATERIALS AND MEmODS: Non-pregnant adulr sheepwith hormonal control were chosen to perform ex-

PURPOSE: To determine the optimal embolic panicle toachieve complete devascularization of the fibroids with­out necrotic effect on adjacent normal myometrium andischemic damage to the ovaries.

Uterine Fibroid Embolization: Choice of anEmbolic Particle

Jj. Pelage, Parts, France • A. Lau1'ent • M. Wassel.M. Bonneau • R. Rymer. j. Merland

189

Abstract No. 5112:52 pm

RESULTS: All specimens treated with EMBOLYX showedno angiographic evidence of recanalization. At sacrifice alluteri grossly appeared normal. The only instance of en­dometrial necrosis occurred in a single sheep embolizedwith PYA bilaterally. Both agents were seen to penetrateto similar size vessels (400-500 microns). The microscopicchanges seen with both agents was identical and con­sisted of intimal hyperplasia and foreign body reactionwith the presence of giant cells. PYA panicles were seenmicroscopically in 94% of uterine segments when bilateralembolization was successful whereas, EMBOLYX panicleswere seen in only 46%. No evidence of ovarian infarctionwas seen with either agent. Permanent main uterine ar­tery occlusion was the rule with EMBOLYX; while all uter­ine arteries remained patent following the use of PYA.

12:41 pm Abstract No. 50

Uterine Artery Embolization in the Sheep ModelUsing a New Embolic Agent, Embolyx

JI. SWischuk, Peoria, I1 • F Castaneda • R. Ii • K. Young

PURPOSE To determine the depth of penetration andthe effects of transcatheter uterine artery embolizationwith EMBOLYX in sheep.

MATERIAL AND MElliODS: Uterine arteries of 10 sheepwere embolized with EMBOLYX , Polyvinyl alcohol par·ticles (PYA) or both. Three sheep were embolized withPYA (350-500 microns), four sheep were embolizedwith EMBOLYX (two each with 6.5% andl0% solutions)and three sheep had one uterine artery embolized withPYA and the other with EMBOLYX (6.5%). Successfulembolization was achieved in 18 uterine alteries. All an­imals were sacrificed at 3-4 weeks. The uteri andovaries were explanted and examined macroscopicallyand microscopically. Microscopic sections were takenthrough the main uterine artery, ovaries and the body,and horns (proximal, mid, and distal) of the uteri to de­termine the distribution of embolic agents.

CONCLUSION: EMBOLYX appears to be safe, causingsimilar microscopic changes when compared to PYA.uterine infarction did not occur with the use of EM­BOLYX. Although both agents penetrated to similar lev­els, the distribution of EMBOLYX throughout the uteruswas more sporadic. In addition, Embolyx causes moreproXimal occlusion when compared to PYA.

Scientific Session 7UFE: Technical DevelopmentsModerator: Lindsay Machan, MD

Monday, March 27, 200012:30 pm-2:00 pm

12:30 pm Abst....dct No. 49

The Feasibility of Perfonning Uterine FibroidEmbolization as an Outpatient Procedure:Experience in 73 Patients

GoP Siskin, Albany, NY • B.F Siainken • K. Dowling •

P Mea • j. AIm • E.G. Dolen

PURPOSE: To assess the feasibility of performing uter­ine fibroid embolization as an outpatient procedure.

MATERIALS AND MElliODS: 73 consecutive patients(mean age 44.3 years) underwent uterine artery<None>embolization during a 12-month period. Em­bolizaton was performed with 350-500u polyvinyl al­cohol particles (67173) or gelfoam pledgets (6173). Atdischarge, patients were given instructions regardingthe expected symptoms after embolization and wereprescribed Prochlorperazine, Ketorolac, Meperidine,and Hydrocodone for symptomatic relief. All patientswere telephoned within 24 hours of discharge. Dur­ing follow-up, a questionnaire was administered toevaluate the periprocedural experience. 3-monthclinical follow-up is available in 42 patients and im­aging was performed at 6 months in 22 patients.

RESULTS: Presenting symptoms included menorrhagia(n=25), bulk-related symptoms including distension,incontinence, or pain (n=l1), or both (n=37). 71173patients were discharged 6-8 hours after emboliza­tion; 2 patients required overnight observation 0 dueto post-procedure hypertension and 1 due to a lateprocedure completion time). At the first follow-upphonecall, symptoms included pelvic pain in 82.2%(60173), fatigue in 75.3% (55173), nausea/vomiting in43.8% (32/73) and a vaginal discharge in 17.8%(3173). 5 patients called our staff to obtain additionalmedication instfllctions(n=3) or to request additionalmedication for pain control (n=2). Symptoms werecontrolled with discharge medications in 71/73 pa­tients. 1 patient visited the emergency room and re­quired admission for additional pain control duringthe first 48 hours after discharge. 69/73 patients weresatisfied with the decision for home discharge. Themean uterine volume reduction in 22 patients imagedat 6 months was 49.2%. 88.1% of patients with 3­month clinical follow-up reported improvement orelimination of symptoms.

CONCLUSION: With defined telephone follow-up, staffavailability, and a protocol designed to alleviate thepost-procedure constitutional symptoms, uterine arteryembolization can be safely performed as an outpatientprocedure without sacrificing patient comfort.

190

peri mental uterine embolization because of uterine blood supply similar ro that of human. Four different sizes, 150-250, 250-400, 400--<)00 and 600-1000~m of PYA pal1icles (Ultra-Ivalon, Nycomed, France) and four sizes, 100-300, 300-500, 500-700 and 700-900~m of calibrated microspheres (Embosphere , Biosphere Med­ical, USA) were compared in 8 groups of animals sacri­ficed 5 days after embolization. Ease of injection and angiographic occlusion were compared. Embolic parti­cles were also compared according ro MR imaging stud­ies and histopathologic fearures (uterine necrosis and location of the particles).

RESULTS: No occlusion of the 5-French catheter was ob­served with microspheres even of 700--900pm diameter. Score of urerine necroSis was higher with small panicles (diameter<300~m) than with larger particles (p=O.02). Necrosis was higher with 150-250pm PYA particles (SO% of the uterus) than with 100--300pm calibrated mi­crospheres (300/0 of tbe uterus) (p<O.OS). Uterine necro­sis was less than 5% of the uterus, using large micros­phe res. All types of PYA particles were located proximally in aggregates and distally (vessels ranging from 300 to 1000pm). Conversely, the diameter of oc­cluded arteries was well correlated with the size of the microspheres used. Small calibrated microspheres were located distally. Microspheres smaller than SOOpm were occasionaly found inside the ovaries through a patent utero-ovarian anasromosis.

CONCLUSIONS: Our specific experimental model pro­vides comprehensive assessment of physiopathologic uterine response to embolization. PYA particles are as­socia ted with intense uterine necrosis and extensive ar­terial occlusion. Calibrated microspheres which are as­sociated with less necrosis permit a more controlled a([erial occlusion than PYA particles. Panicles larger than 500pITI should not reasonably be used in clinical practice to avoid ischemic damage on the ovaries.

Supported in part by a grant from the French Society of Radiology (SFR)

Abstr.u..1: No. 52

Measurements of Skin Dose and Estimated Ovarian Dose Associated With Uterine Fibroid EmboUzatioll! A Follow-Up Study With Rerrned

Technique and State of the Art Equipment B. Nikolic, Washington, DC • IE. Spies . S.M. Walsh. ML Lundsten . AR. Roth

PURPOSE: To determine the absorbed skin dose (ASD) and estimated absorbed ovarian dose (EAOD) that oc­cu rs during uterine fibroid embolization (UFE) using re­fined technique and srate-of-the-al1 equipment.

METHOD AND MATERIAL The absorbed dose was measured in 12 patienrs who underwent UFE proce­dures. All UFE procedures were performed using low frequency pulsed fluoroscopy with focus on limitation of magnified and oblique fluoroscopy . Lithium fluoride

dosimeters were placed both in the posterior vaginal fornix and on the skin at the beam entrance site. The vaginal dose was used to approximate the EAOD. Fluo­roscopy time and exposures were recorded. The mean values for all patients were calcu lated and compared to published EAODs for other conunon radiographic and radiotherapeutic procedures, to threshold doses for in­duction of deterministic skin injury and to our previous measurements from UFE procedures mat were obtained with non-pulsed fluoroscopy.

RESULTS: Mean fluoroscopy time was 13 min. (range 7.6-21.3 min) and mean number of angiographic expo­sures was 17 (range 14--22). The mean EAOD was 11.0 cGy (range 2.2- 23.2 cGy) and the mean ASD was 57.42 cGy (range 12.9- 110. 1). This compares to published values of EAOD for double contrast BE (0.311-0.79 cGy), hysterosalpingiography (0.075-0.374 cGy), fallop­ian tube recanalization (0.85 cGy), UFE with non-pulsed fluorosocpy (22.34 cGy, range 4.25-65.08 cGy) and threshold doses for induction of determirtistic radiation injury to the skin (300-500 cGy).

CONCLUSION The ASD and EAOD from UFE proce­dures performed with refined technique and the use of state-of-the-alt equipment remains an order of magni­tude grea ter than from common fluoroscopic proce­dures. However, using pulsed fluorosocpy with empha­sis on reduction of absorbed radiation dose, can substantially reduce ASD and EAOD to 1/3 and 112 when compared to UFE performed with non-pulsed flu­oroscopy.

Abstract No_ 53

The Impact of a Public Awareness Campaign on Referrals for Uterine Fibroid EmboUzation

GP. Siskin, Albany, NY • B.F. Stainken • K. Dowling. I Ahn • E.G. Dolen · P Moo

PURPOSE: To determine the impact of a public aware­ness campaign regarding uterine fibroid embolization on referral patterns for this procedure.

MATERIALS AND ME'flfODS: A retrospective analysis was performed on all patienrs arranging consultations regarding uterine fibroid embolization. All patients were asked where they first learned about uterine fibroid em­bolization and the source(s) of their referraL Referral patterns and the effects of the techniques utilized to raise public awareness were then determined.

RESULTS: 114 patients (mean age 43.9 years; range 28-59 years) were included in this srudy. All patients were seen in consultation by an lnterventional radiolo­gist [Q discuss uterine fibroid embolization. A gynecolo­gist referred 43/114 (37.7%) patients for consultation; 33/43 (76.7%) were referred by private practice gyne­cologists and 10/ 43 (23.3%) were referred by academic staff gynecologists. 71 / 11 4 (62.3%) patients were self-re­ferred after learning about the procedure from televi­sion news (32/ 114; 28.1%), the internet (211114; 18.4%),

The Impact of a Public Awareness Campaign onReferrals for Uterine Flbroid EmbolIzation

G.P. Siskin, Albany, NY • B.F Stainken • K. Dowling.j. Ahn • E.G. Dolen· P. Moo

PURPOSE: To determine the impact of a public aware­ness campaign regarding uterine fibroid embolizationon referral patterns for this procedure.

dosimeters were placed both in the posterior vaginal

fornix and on the skin at the beam entrance site. Thevaginal dose was used to approximate the EAOD. Fluo­roscopy time and exposures were recorded. The meanvalues for all patients were calculated and compared topublished EAODs for other conunon radiographic andradiotherapeutic procedures, [0 threshold doses for in­duc[ion of deterministic skin injury and to our previous

measurements from UFE procedures that were obtainedwith non-pulsed fluoroscopy.

RESULTS: Mean fluoroscopy time was 13 min. (range7.6-21.3 min) and mean number of angiographic expo­sures was 17 (rartge 14-22). The mean EAOD was 11.0cGy (range 2.2-23.2 cGy) and the mean ASD was 57.42cGy (range 12.9-110.1). This compares to publishedvalues of EAOD for double contrast BE (0.311-0.79cGy), hysterosalpingiography (0.075-0.374 cGy), fallop­ian tube recanalization (0.85 cGy), UFE with non-pulsedfluorosocpy (22.34 cGy, range 4.25-65.08 cGy) andthreshold doses for induction of determirtistic radiation

injury to the skin (300-500 cGy).

CONCLUSION The ASD and EAOD from UFE proce­dures performed with refined technique and the use ofstate-of-the-alt equipment remains an order of magni­tude greater than from common fluoroscopic proce­dures. However, using pulsed fluorosocpy with empha­sis on reduction of absorbed radiation dose, cansubstantially reduce ASD and EAOD to 1/3 and 1/2when compared to UFE performed with non-pulsed flu­oroscopy.

peri mental uterine embolization because of uterineblood supply similar ro that of human. Four different

sizes, 150-250, 250-400, 400--600 and 600-1000~m ofPYA pal1icles (Ultra-Ivalon, Nycomed, France) and foursizes, 100-300, 300-500, 500-700 and 700-900~m ofcalibrated microspheres (Embosphere, Biosphere Med­ical, USA) were compared in 8 groups of animals sacri­ficed 5 days after embolization. Ease of injection andangiographic occlusion were compared. Embolic parti­cles were also compared according ro MR imaging stud­ies and histopathologic fearures (uterine necrosis andlocation of the particles).

RESULTS: No occlusion of the 5-French catheter was ob­served with microspheres even of 70G-900pm diameter.Score of uterine necrosis was higher with small panicles(diameter<300~m) than with larger particles (p=O.02).

Necrosis was higher with 15D-250pm PYA particles(500/0 of the uterus) than with lOQ-300pm calibrated mi­crospheres (30% of the uterus) (p<0.05)' Uterine necro­

sis was less than 5% of the uterus, using large micros­

pheres. All types of PYA particles were locatedproximally in aggregates and distally (vessels rangingfrom 300 to 1000pm). Conversely, the diameter of oc~

c1uded arteries was well correlated with the size of themicrospheres used. Small calibrated microspheres were

located distally. Microspheres smal1er than SOOpm wereoccasionaly found inside the ovaries through a patentutero-ovarian anastomosis.

CONCLUSIONS: Our specific experimental model pro­vides comprehensive assessment of physiopathologicuterine response to embolization. PYA particles are as­sociated with intense uterine necrosis and extensive ar­terial occlusion. Calibrated microspheres which are as­sociated with less necrosis permit a more controlledarterial occlusion than PYA particles. Particles largerthan 500pITI should not reasonably be used in clinicalpractice to avoid ischemic damage on the ovaries.

Supported in part by a grant from the French Society ofRadiology (SFR)

1:14 pm Abstract No. 53

Measurements of Skin Dose and EstimatedOvarian Dose Associated With Uterine FibroidEmbolJzation: A Follow-Up Study With Rerrned

Technique and State of the Art EquipmentB. Nikolic, Washington, DC • j.B. Spies.S.M. Walsh. M.L. Lundsten. A.R. Roth

1:03 pm Abstr.u...1: No. 52 MATERIALS AND ME71-IODS: A retrospective analysiswas performed on all patients arranging consultationsregarding uterine fibroid embolization. All patients wereasked where they first learned about uterine fibroid em­

bolization and the source(s) of their referral. Referralpatterns and the effects of the techniques utilized to

raise public awareness were then determined.

190

PURPOSE: To determine the absorbed skin dose (ASD)and estimated absorbed ovarian dose (EAOD) that oc­curs during uterine fibroid embolization (UFE) using re­fined technique and st3te-of-the-al1 equipment.

MEIHOD AND MATERIAL The absorbed dose was

measured in 12 patienrs who underwent UFE proce­dures. All UFE procedures were performed using low

frequency pulsed fluoroscopy with focus on limitationof magnified and oblique fluoroscopy. Lithium fluoride

RESULTS: 114 patients (mean age 43.9 years; range28-59 years) were induded in this srudy. All patientswere seen in consultation by an interventional radiolo­gist to discuss uterine fibroid embolization. A gynecolo­gist referred 43/114 (37.7%) patients for consultation;33/43 (76.7%) were referred by private practice gyne­cologists and 10/43 (23.3%) were referred by academicstaff gynecologists. 71/114 (62.3%) patients were self-re­ferred after learning about the procedure from televi­sion news (32/114; 28.1%), the internet (21/114; 18.4%),

PURPOSE- To determine the efficacy and safety of treat­ment of uterine leiomyomata and concomitant adeno­myosis with uterine fibroid embolization (UFE).

Uterine Fibroid Embolization in Patients WithLeiomyomata and Concomitant Adenomyosis:Experience in Thirteen PatientsI W Thomas, Washington, DC • IT Gomez-jorge •

TC. Chang • R.C.]ha • S.M. Walsh • lB. Spies

MATERIALS AND METHODS: One hundred and seventy­one patients with symptomatic leiomyomata weretreated at our institution between 1997 and 1999. Thir­teen (13) of these patients had concomitant adeno­myosis on baseline MRI evaluation. Bilateral UFE wasperformed and follow up questionnaires were obtainedat 3 months (n=13), 6 months (n=10) and 1 year (n=5)and follow up Mill examinations were obtained at 3months (n=13) and one year (n=4).

Abstract No. 551:36 pm

Bilateral Uterine Artery Embolization for theTreatment of Menorrhagia Due to AdenomyosisG.P. Siskin, Albany, NY • ME Tublin • B.P. Stainken •

K. Dowling • I Ahn • E. G. Dolen

PURPOSE- To evaluate the use of bilateral uterine arteryembolization in the treatment of menorrhagia due toadenomyosis.

MATERIALS AND MElliODS: 14 patients (mean age46.7 years, range 37-56 years) with adenomyosis andmenorrhagia underwent bilateral uterine artery em­bolization. The diagnosis of diffuse adenomyosis wasbased on a maximum junctional zone thickness ~12

rom. at fast spin echo imaging. Focal adenomyosis wasdiagnosed if there was focal thickening of the junc­tional zone. Uterine artery embolization was per­formed with standard technique, utilizing 350-5001l

polyvinyl alcohol particles. Clinical response wasmeasured with a questionnaire administered 3 and 6months follOWing embolization. Follow-up MRI wasperformed 6 months after embolization.

CONCLUSIONS: Our limited experience suggests thatuterine artery embolization may be effective in treatingsymptomatic uterine leiomyomata despite the pres­ence of adenomyosis. The majority of patients experi­ence symptomatic relief, decrease in size of leiomy­omata and uterine volume despite stable appearanceof the adenomyosis.

RESULTS: Bilateral uterine artery embolization was tech­nically successful in all patients. Diffuse adenomyosiswas present in 10/14 patients with a mean junctionalzone thickness of 18.1 mm. (range 12-30 rom.). Focaladenomyomas were present in 4/14 patients. 9/14 pa­tients had uterine fibroids in addition to adenomyosis.3-month clinical follow-up is available in 11/14 patients.6-month clinical and imaging follow-up is available in6/14 patients. At 3 months, 10/11 patients (90.1%) re­ported significant improvement of their presentingsymptoms while 1/11 reported no change. Follow-upimaging at 6 months demonstrated a mean decrease inuterine volume of 47.6% (range 27.9-65.0%). The meandecrease in volume of the 3 focal adenomyomas im­aged at 6 months was 74.3%. In 3 patients with diffuseadenomyosis, the mean decrease in junctional zonethickness was 39.4% at 6 months. 5/6 patients imaged at6 months had fibroids as weJJ as adenomyosis; themean decrease in fibroid volume was 57.4%.

oma of 52% (n=13). MRI at one year (n=4) showed amean decrease in uterine volume of 44%, and decreasein volume of dominant leiomyoma was 87%. No signifi­cant change in the MRI appearance of adenomyosis wasnoted at 3 months and one year.

CONaUSIONS: Bilateral uterine artery embolization effec­tively proVides symptomatic relief in patients with adeno-myosis and menorrhagia. In addition, embolization results 191

Abstract No. 541:25 pm

CONCLUSION- Most patients arranging a consultationto discuss uterine fibroid embolization were self-re­ferred after learning about the procedure from televi­sion news, newspaper articles, and the Internet. Uti­lizing a hospital's public relations resources andestablishing a presence on the Internet are thereforecritical first steps in starting a uterine fibroid em­bolization service. The single largest referral sourceremains the gynecologist, stressing the importance ofeducating and developing ties with staff and commu­nity gynecologists.

a family member of friend (9/114; 7.9%), newspaper ar­ticles (8/114; 7.0%), or other other sources includingradio broadcasts, magazines, health fairs, and primarycare physicians. 78/114 (68.4%) of patients undergoinga consultation decided to undergo this procedure. Themean delay between the consultation and procedurewas 54.1 days. There was no significant difference inthe distribution of referral sources between the patientsscheduling or not scheduling the procedure after con­sultation (X2=2.023; p~0.20).

RESULTS: Technical success was achieved in all patientswith uterine leiomyomata and concomitant adeno­myosis, without complications (n=13). At 3 months,92% (12/13) reported moderate to marked improve­ment in bleeding, 92% (11/12) moderate to marked im­provement in pain/pressure, and 92% (12/13) overallsatisfaction with treatment. At 6 months, 90% (9/10) re­ported moderate to marked improvement in bleeding,750/0 (6/8) moderate to marked improvement inpain/pressure, and 67% (6/9) overall satisfaction withthe procedure. At one year, 80% (4/5) reported moder­ate to marked improvement in bleeding, 100% (3/3)

moderate to marked improvement in pain/pressure,and 60% (3/5) overall satisfaction with procedure. MRIat 3 months showed a mean decrease in uterine volumeof 39% (n=12), and mean decrease in dominant leiomy-

in decreases in uterine volwne, focal adenomyoma volume,and junctional zone thickness in this patient population.

PURPOSE: To evaluate the potential usefulness oftranscatheter uterine artery embolization as a treat­ment for symptomatic adenomyosis oUhe utefl.ls.

Uterine Arterial Embolization for the Treatmentof Symptomatic Adenomyosis of the Uterus

C. Ahn, Sungnam, South Korea • WH. Lee·

T. W Sunwoo • YS. Kho

MATERIALS & ME71iODS: Uterine arterial emboliza­tion using polyvinyl alcohol particles sized 250-710micrometers was performed in 65 pa'tients (mean;40.6 years, range; 25-53 years) w(th dysmenorrhea,menorrhagia, or bulk-related symptoms (heaviness,urinary frequency) due to adenomyosis. All patieatswere evaluated with contrast enhanced dynamicmagnetic resonance imaging (MRl) before the proce­dure and 35 months (range; 31-238 days) after. Clin­ical symptoms were also assessed at the time of MRIbefore and after embolization.

RESULTS: Implantation success was 173/180 (96.1%)overall, and 99/101 (98%) after Jan 1, '98; 2/7 failuresreqUired immediate conversion to open repair (1.1%);5/7 were simply aborted. Though 3/392 AAAs rupturedduring the preliminary workup and planning (2 died, 1survived emergency operation elsewhere), no patient(0%) has experienced AAA rupture after TE. Operativemortality (30d) was 7/180 (3.9%), Major non-fatal peri­operative complications occurred in 29/180 06.1%). Av­erages for LOS were: median=3d, mode=2d,mean=4.0±3.1d. There were 9 late deaths unrelated toTE. Of .32 (17.8%) patients with endoleaks, 3 self-re­solved, 5 died of unrelated causes, 5 undetwent secondreparative TE, 5 open surgical repair, 3 embolization, 11are still under observation.

PURPOSE: To report our single-center results of abdom­inal aortic aneurysm (AAA) repair by transluminal endo­grafting (TE).

ME71-JODS: ]80 TE were attempted from 3/94-10/99 inaverage to extremely high risk AAA patients, age 53 to

94 yrs, 1J=73±8.2. In each case the TE physician teamcomprised a senior JR, 1 JR fellow, vascular surgeon,surgical asst., anesthesiologist. Epidural anesthesia andbifemoral access were used in almost all cases. Fol­lowup included Hx, PE, spiral CT. Data sources werecharts, case report forms, and since 1/96, computerizedmedical records. Fifteen TE procedures were performedfrom 3/94 to 12/95. Office consults from 1/96-10/99 in­cluded 392 AAA patients: 360 (91.8%)M; 32 (8.2%)F.Overall 1581.360 (43.9%) men, but only 7/32 (21.9%)women undetwent TE. Most exclusions in women weredue to small iliacs. The other 227/392 had open surgeryor are under observation for smaller AAAs. TE deviceswere home-made, n=9; EVT (Guidant), n=62; Talent(Medtronic-World Medica!), n=55; Vanguard (BostonScientific), n=29, Excluder (W.L. Gore & Associates),n=25. Configurations were: bifurcated 88%, tube 6%,and unilateral aortoiliac+cross-femoral graft 6%.

CONCLUSION TE is a safe, effective treatment for AAA,even in high-risk patients. LOS is short. Endoleak pre­vention and management are among the greatest chal­lenges we face today.

Abstract No. 56

FEATURED ABSTRACTCommentator: James B. Spies, MD

RESULTS: At 3.5 months follow-up, 61 of 65 1'a­tients(93.8%) reported improvement of the symp­toms. Contrast enhanced dynamic MRI revealednon-enhancing ·areas at the previously noted ade­nomyosis suggesting coagulation necrosis in 44 pa­tients (67.7%), decreased size of adenomyosis in 17patients (26.1%), and no change of adenomyosis in4 patients (6.2%). 6 patients (mean age; 45.2 years,age range; 40-53 years) b~came amenorrheic.

CONCLUSION Particulate transcatheter uterine arte­rial embolization is an effective therapy for the treat­ment of symptomatic adenomyosis and may be avaluable alternative to hysterectomy, or other surgi­cal procedures. Further investigation is warranted.

1:47 pm

Scientific Session 8Stent-Grafts for AAA: Clinical TrialsModerator: James F Benenati, MD

First Five and One-Half Years Experience WithTransluminal Endografting for Abdominal AorticAneurysm

Gj. Becker, Miami, PI • M. Kovacs • B.T. Katzen •

IF Benenati • G. Zemel • A. Powell, et al192

Monday, March 27,200012:30 pm-2:00 pm

12:30 pm Abstract No. 57

12:41 pm Abstract No. 58

Early Clinical Experience in the Treatment ofInfrarenal Aortic Aneursyms Utilizing the AneuRxBifurcated Stent-Graft System

RA. White, Torrance, CIl • C.E. Donayre • I. Walot •G. Kopchok

PURPOSE: To evaluate the safety, efficacy and ease ofuse of the AneuRx Stent-Graft System in the endolu­minal treatment of infrarenal abdominal aorticaneurysms (AAAs).

ME7HODS: Endovascular t.reatment of infrarenal AAAwas attempted in 171 patients (155 male/16 female)ranging in age from 46-90 years (mean 73.4 years).